CLAIMS

1. Use of an immunoconjugate which binds to FOLR1 polypeptide in the manufacture of a medicament for the treatment of a FOLR1 expressing cancer, wherein the immunoconjugate comprises an antibody or antigen-binding fragment thereof that comprises the variable light chain (VL) complementarity determining region (CDR)-1 of SEQ ID NO: 6, the VL CDR-2 of SEQ ID NO: 7, the VL CDR-3 of SEQ ID NO: 8, the variable heavy chain (VH) CDR-1 of SEQ ID NO: 9, the VH CDR-2 of SEQ ID NO: 11, and the VH CDR-3 of SEQ ID NO: 12, and a maytansinoid, and wherein the immunoconjugate is to be administered at a dose of 6 milligrams (mg) per kilogram (kg) of adjusted ideal body weight (AIBW) of a human patient.

2. The use of claim 1, wherein the administration produces a Cmax of about 90-160 μg/mL.

3. The use of claim 2, wherein the administration produces a Cmax of about 90-150 μg/mL.

4. The use of any one of claims 1-3, wherein the administration produces an area-under-the-curve $(AUC)_{0-24}$ of no more than 2700 hr•μg/mL.

5. The use of any one of claims 1-4, wherein the immunoconjugate is to be administered once every three weeks.

6. The use of any one of claims 1-4, wherein the immunoconjugate is to be administered once every four weeks.

7. Use of an immunoconjugate which binds to FOLR1 polypeptide in the manufacture of a medicament for the treatment of a FOLR1 expressing cancer, wherein the immunoconjugate comprises an antibody or antigen-binding fragment thereof that comprises the variable light chain (VL) complementarity determining region (CDR)-1 of SEQ ID NO: 6, the VL CDR-2 of SEQ ID NO: 7, the VL CDR-3 of SEQ ID NO: 8, the variable heavy chain (VH) CDR-1 of SEQ ID NO: 9, the VH CDR-2 of SEQ ID NO: 11, and the VH CDR-3 of SEQ ID NO: 12, and a maytansinoid, and wherein the immunoconjugate is to be administered at a dose of 6 milligrams (mg) per kilogram (kg) of adjusted ideal body weight (AIBW) of a human patient, and wherein the administration produces a Cmax of about 110-160 μg/mL.

8. Use of an immunoconjugate which binds to FOLR1 polypeptide in the manufacture of a medicament for the treatment of a FOLR1 expressing cancer, wherein the immunoconjugate comprises an antibody or antigen-binding fragment thereof that comprises the variable light chain

(VL) complementarity determining region (CDR)-1 of SEQ ID NO: 6, the VL CDR-2 of SEQ ID NO: 7, the VL CDR-3 of SEQ ID NO: 8, the variable heavy chain (VH) CDR-1 of SEQ ID NO: 9, the VH CDR-2 of SEQ ID NO: 11, and the VH CDR-3 of SEQ ID NO: 12, and a maytansinoid, and wherein the immunoconjugate is to be administered at a dose of 6 milligrams (mg) per kilogram (/kg) of adjusted ideal body weight (AIBW) of a human patient, and wherein the administration produces an AUC_{0-24} of no more than 2700 hr•μg/mL.

9. The use of any one of claims 1-8, wherein the antibody comprises (i) a heavy chain comprising the same amino acid sequence as the amino acid sequence of the heavy chain encoded by the plasmid deposited with the American Type Culture Collection (ATCC) as PTA-10772 and (ii) a light chain comprising the same amino acid sequence as the amino acid sequence of the light chain encoded by the plasmid deposited with the ATCC as PTA-10774.

10. The use of any one of claims 1-9, wherein the maytansinoid is DM4.

11. The use of any one of claims 1-10, wherein the immunoconjugate comprises the linker sulfo-SPDB.

12. The use of any one of claims 1-11, wherein the immunoconjugate comprises DM4 and an antibody comprising (i) a heavy chain comprising the same amino acid sequence as the amino acid sequence of the heavy chain encoded by the plasmid deposited with the American Type Culture Collection (ATCC) as PTA-10772 and (ii) a light chain comprising the same amino acid sequence as the amino acid sequence of the light chain encoded by the plasmid deposited with the ATCC as PTA-10774, and wherein the DM4 is linked to the antibody by sulfo-SPDB.

13. The use of any one of claims 1-11, wherein the immunoconjugate comprises DM4 and an antibody comprising (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 13 and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 15, and wherein the DM4 is linked to the antibody by sulfo-SPDB.

14. The use of any one of claims 1-13, wherein the immunoconjugate is formulated for IV administration.

15. The use of any one of claims 1-14, wherein said cancer is selected from the group consisting of ovarian, brain, breast, uterine, endometrial, pancreatic, renal, lung cancer, and cancer of the peritoneum.

16. The use of claim 15, wherein the lung cancer is non small cell lung cancer.

17. The use of claim 15, wherein the cancer is cancer of the peritoneum.

18. The use of claim 15, wherein the ovarian cancer is epithelial ovarian cancer.

19. The use of claim 18, wherein the ovarian cancer is platinum resistant, relapsed, or refractory.

20. The use of claim 15, wherein the cancer is endometrial cancer.

21. The use of any one of claims 1-20, wherein a sample obtained from the patient exhibits FOLR1 expression as measured by immunohistochemistry (IHC).

22. The use of claim 21, wherein the sample has a staining intensity of at least 2 hetero.

23. The use of claim 21, wherein the sample has a staining intensity of at least 2 homo.

24. The use of claim 21, wherein the sample has a staining intensity of at least 3 hetero.

25. The use of claim 21, wherein the sample has a staining intensity of at least 3 homo.

26. The use of any one of claims 1-25, wherein the medicament is for administration with a steroid.

27. The use of claim 26, wherein the steroid is dexamethasone.

28. The use of any one of claims 1-15, 18, 19, and 21-27, wherein the cancer is ovarian cancer and wherein the administration results in a decrease in CA125.

29. The use of any one of claims 1-28, wherein the immunoconjugate comprises 1-10 maytansinoid molecules.

30. The use of any one of claims 1-28, wherein the immunoconjugate comprises 2-5 maytansinoid molecules.

31. The use of any one of claims 1-28, wherein the immunoconjugate comprises 3-4 maytansinoid molecules.

32. The use of any one of claims 1-31, wherein the administration results in a decrease in toxicity.

33. The use of claim 32, wherein the toxicity is ocular toxicity.

34. Use of an immunoconjugate which binds to FOLR1 polypeptide in the manufacture of a medicament for the treatment of a FOLR1 expressing cancer, wherein the immunoconjugate comprises an antibody or antigen-binding fragment thereof that comprises the variable light chain (VL) complementarity determining region (CDR)-1 of SEQ ID NO: 6, the VL CDR-2 of SEQ ID NO: 7, the VL CDR-3 of SEQ ID NO: 8, the variable heavy chain (VH) CDR-1 of SEQ ID NO: 9, the VH CDR-2 of SEQ ID NO: 11, and the VH CDR-3 of SEQ ID NO: 12, and a maytansinoid, and wherein the immunoconjugate is to be administered at a dose of 6 milligrams (mg) per kilogram (kg) of adjusted ideal body weight (AIBW) of a human patient, and wherein the administration is to occur once a week for three weeks on a four-week schedule.